8-K: Monogram Technologies Upsizes Convertible Preferred Stock and Warrant Offering to $12.5 Million

Monogram Technologies has increased its continuous offering of units, each consisting of preferred stock and a warrant, from $10 million to $12.5 million.

Summary

• Monogram Technologies has announced an increase to its ongoing offering of units, raising the total from $10 million to $12.5 million.
• Each unit includes one share of 8.00% Series D Convertible Cumulative Preferred Stock and one common stock purchase warrant.
• The warrants become exercisable 180 days after July 9, 2024, and expire on July 8, 2025, unless redeemed earlier.
• The warrant exercise price is $3.375 per share, which is 150% of the unit's public offering price.
• The preferred stock and warrants can be traded separately after purchase, but are sold together as a unit.
• The preferred stock is convertible into common stock at the holder's option.
• The company does not plan to list the preferred stock or warrants on any exchange.
• Dividends on the preferred stock may be paid in cash or common stock at the company's discretion.
• The funds raised will be used for general corporate purposes, operational needs, new technology development, and potential acquisitions.
• The offering is expected to close after subscriptions cease at midnight PT on Thursday, September 12th.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the upsized offering providing additional capital, but tempered by the risks associated with a developing company and the lack of a public market for the preferred stock.

Positives

• The upsized offering provides Monogram Technologies with additional capital to support its strategic initiatives.
• The funds will be used to advance the company's mission of transforming orthopedic surgeries.
• The offering allows for flexibility in dividend payments, which can be made in cash or common stock.
• The company has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products.

Negatives

• There is no existing public trading market for the Series D Preferred Stock.
• The company does not intend to list the preferred stock or warrants on a national securities exchange or quoted on an over the counter market.
• The company cannot estimate the timing or assure the ability to obtain FDA clearances for its robotic products.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties.
• Actual results may vary materially from forward-looking statements due to factors described in the prospectus and SEC filings.
• The company is required to obtain FDA clearance before it can market its products, and there is no guarantee of obtaining such clearances.
• The company is an emerging growth company and may have less stringent reporting requirements.

Future Outlook

The company intends to use the proceeds from the offering for general corporate and business purposes, operational needs, and to fund various strategic initiatives, including new technology development and potential acquisitions. The company anticipates that there may be other clinical and commercial applications for its navigated mBs precision robot and mVision navigation.

Management Comments

• We are pleased to be in a position to upsize the offering and further advance Monogram's mission of transforming orthopedic surgeries, said Benjamin Sexson, CEO of Monogram Technologies.
• These funds will provide us with additional resources to support key initiatives as we continue to innovate within the orthopedic market.

Industry Context

This announcement is relevant to the medical technology and robotics sectors, particularly companies focused on orthopedic surgery. The company's focus on AI-driven robotics and personalized implants aligns with current trends in the industry.

Comparison to Industry Standards

• Monogram's approach to combining 3D printing, AI, and robotics for orthopedic implants is similar to other companies in the space, such as Stryker and Zimmer Biomet, who are also investing in robotic surgery and personalized medicine.
• However, Monogram is a smaller company and is still in the process of obtaining FDA clearances for its robotic products, while larger competitors already have established product lines and market presence.
• The 8% dividend on the preferred stock is relatively high, which may be attractive to investors seeking income, but also reflects the higher risk associated with a smaller, developing company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees may benefit from the additional resources for development and growth.
• Customers may benefit from the company's continued innovation in orthopedic surgery.
• Creditors may see the company as a more stable investment due to the increased capital.

Next Steps

• The company will complete the offering, which is expected to close after subscriptions cease at midnight PT on Thursday, September 12th.
• The company will use the proceeds for general corporate purposes, operational needs, new technology development, and potential acquisitions.
• The company will continue to pursue FDA clearance for its robotic products.

Key Dates

Keywords

Monogram Technologies, Convertible Preferred Stock, Warrants, Capital Raise, Orthopedic Surgery, Robotics, AI, FDA Clearance, mPress Implants, mBs precision robotic surgical system